This strengthens type 1 conventional dendritic cell (cDC1)–mediated cross-priming and expands tumor-specific CD8+ T cells, creating synergy with PD-1 blockade and improving antitumor efficacy (199–201). This evidence concerns the gene CD8A and neoplasm.